AstraZeneca helped in competitive debate by Gilead’s EVOKE-01 miss, says BofA

BofA notes that Gilead’s (GILD) Trodelvy Phase 3 EVOKE-01 trial missed its OS primary endpoint, “largely as we had expected,” adding that the second line lung study is equivalent to AstraZeneca’s (AZN) datopotamab TL01 and calling the result “a directional positive” for AstraZeneca’s datopotamab. The firm had flagged risk to the EVOKE study given AstraZeneca’s study also missed OS, noting that TL01 had dual co-primary PFS and OS endpoints, while for EVOKE-01, OS was the only primary. There is no PFS data available for Gilead, with positive PFS data the basis for AstraZeneca’s filing, added the analyst, who keeps a Buy rating on AstraZeneca shares.